Progression of HER-2 lowly expressed breast cancer and the related anti-tumor drugs
10.3760/cma.j.cn112152-20210220-00149
- VernacularTitle:人表皮生长因子受体2低表达乳腺癌及其相关药物治疗的研究进展
- Author:
Peng YUAN
1
;
Binghe XU
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院特需医疗部 100021
- Keywords:
Breast neoplasms;
HER-2 low expression;
Drug;
Treatment
- From:
Chinese Journal of Oncology
2021;43(9):901-905
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is one of the common malignant tumors of women. In recent years, the incidence of breast cancer is high. Human epidermal growth factor receptor-2 (HER-2) is a tyrosine kinase receptor. Breast cancer with abnormal amplification or overexpression of HER-2 have the characteristics of strong tumor invasiveness and poor prognosis. With the advent of anti-HER-2 drugs, the survival period of patients with HER-2 positive breast cancer is gradually prolonged, and the prognosis of patients with HER-2 positive breast cancer is improved. However, the efficacy of traditional HER-2 targeted drugs on patients with low expression of HER-2 is very limited, and the treatment of breast cancer with low expression of HER-2 is still facing challenges. This article reviews the standardization process of the American Society of Clinical Oncology and the American Society of Pathologists guidelines for HER-2 detection, and puts forward the data basis and possibility of defining a new subtype of breast cancer with low expression of HER-2. The birth of a new generation of HER-2 targeting drugs makes it possible to treat patients with low expression of HER-2, which will redefine breast cancer with low expression of HER-2 and provide a new opportunity for the prognosis of patients with low expression of HER-2.
